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OBJECTIVE — Patient-physician race/ethnicity concordance can improve care for minority
patients. However, its effect on cardiovascular disease (CVD) care and prevention is unknown.
We examined associations of patient race/ethnicity and patient-physician race/ethnicity concor-
dance on CVD risk factor levels and appropriate modiﬁcation of treatment in response to high
risk factor values (treatment intensiﬁcation) in a large cohort of diabetic patients.
RESEARCH DESIGN AND METHODS — The study population included 108,555
adultdiabeticpatientsinKaiserPermanenteNorthernCaliforniain2005.Probitmodelsassessed
the effect of patient race/ethnicity on risk factor control and treatment intensiﬁcation after
adjusting for patient and physician-level characteristics.
RESULTS — African American patients were less likely than whites to have A1C 8.0% (64
vs.69%,P0.0001),LDLcholesterol100mg/dl(40vs.47%,P0.0001),andsystolicblood
pressure (SBP) 140 mmHg (70 vs. 78%, P  0.0001). Hispanic patients were less likely than
whites to have A1C 8% (62 vs. 69%, P  0.0001). African American patients were less likely
than whites to have A1C treatment intensiﬁcation (73 vs. 77%, P  0.0001; odds ratio [OR] 0.8
[95% CI 0.7–0.9]) but more likely to receive treatment intensiﬁcation for SBP (78 vs. 71%, P 
0.0001; 1.5 [1.3–1.7]). Hispanic patients were more likely to have LDL cholesterol treatment
intensiﬁcation (47 vs. 45%, P  0.05; 1.1 [1.0–1.2]). Patient-physician race/ethnicity concor-
dance was not signiﬁcantly associated with risk factor control or treatment intensiﬁcation.
CONCLUSIONS — Patientrace/ethnicityisassociatedwithriskfactorcontrolandtreatment
intensiﬁcation, but patient-physician race/ethnicity concordance was not. Further research
should investigate other potential drivers of disparities in CVD care.
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T
herearewell-documentedracialdis-
parities in diabetes prevalence and
mortality. African Americans and
Hispanics have higher diabetes preva-
lence, death rates, and higher rates of se-
rious complications (1). Even after
controlling for access to care and socio-
economic status, diabetes disparities in
the U.S. persist (1). There are also widely
recognized disparities in cardiovascular
risk factors associated with diabetes. Afri-
can American and Hispanic patients with
diabetes are less likely to meet glucose,
cholesterol, or blood pressure targets (2).
The evidence surrounding whether
insured patients of color receive worse
care for diabetes and cardiovascular dis-
ease (CVD) risk factor control is mixed
(3–6). Studies have found signiﬁcant dis-
parities in the likelihood of receipt of
medications (7) and medication intensiﬁ-
cation (8,9). However, several studies
have shown that minority patients re-
ceived equal or better quality processes of
care such as screening and medication in-
tensiﬁcation (4,10–12).
Interpersonal barriers resulting from
language or cultural differences between
patients and physicians may explain a
portion of diabetes management dispari-
ties (13,14). Physicians engage in less pa-
tient-centered communication with
patients of color than with white patients
(15). Patient race/ethnicity has been asso-
ciated with physicians’ assessment of pa-
tient intelligence, feelings of afﬁliation
toward the patient, and beliefs about the
patients’ likelihood of risk behavior and
adherence with medical advice (16,17).
Patient-physician race/ethnicity con-
cordance (the patient and health care pro-
vider having the same race/ethnicity) may
helpbridgeinterpersonalbarriersincarefor
minority patients (18). Race/ethnicity con-
cordance is associated with increased pa-
tient trust in the physician (19) and health
services utilization and satisfaction (20).
However, evidence that race/ethnicity con-
cordance is an important factor in the qual-
ity of health care is mixed (21). No studies
have examined the association among race/
ethnicity concordance, cardiovascular dis-
ease processes of care, and levels of in-
termediate outcomes.
The purpose of this study was to ex-
amine the association of patient race/
ethnicity and patient-physician race/
ethnicity concordance on CVD risk factor
levels and treatment intensiﬁcation in a
large cohort of diabetic patients in an in-
tegrated delivery system.
RESEARCH DESIGN AND
METHODS— Study participants were
members of the Kaiser Permanente
Northern California (KPNC) Diabetes
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prehensive medical care to 3.2 million
members. Patients were selected for the
study if they had diabetes before 1 Janu-
ary2005andwereenrolledwithanactive
drug beneﬁt continuously throughout
2005. Eligible patients were further as-
sessed for the presence of hypertension
and hyperlipidemia using Kaiser Perma-
nente automated clinical databases. Self-
reported race/ethnicity data, obtained
fromKaiserPermanentemembersurveys,
study surveys, and hospitalization data,
were available for 87.3% of patients. Phy-
sician data were obtained from physician
demographicﬁlesmaintainedbyThePer-
manente Medical Group.
The ﬁnal study population consisted
of 108,555 African American, white, and
Hispanic adult diabetic patients and
1,750 physicians. Asian patients were not
included in this analysis because, with
current data limitations, ethnically dis-
similar Asian patients and physicians
would be considered race/ethnicity con-
cordant, despite potentially signiﬁcant
cultural and language differences.
Deﬁnition of dependent variables:
good versus poor risk factor control
Threemeasuresofriskfactorcontrolwere
used as dependent variables in this study.
Good A1C risk factor control for diabetes
was deﬁned as a patient having an A1C
laboratory value of 8.0% throughout
2005; this level is in accordance with
quality guidelines at KPNC. Good risk
factor control for patients with hyperten-
sion was deﬁned as not having two or
more consecutive systolic blood pressure
(SBP) readings 140 mmHg at any time
during the year. This level is higher than
that in the Seventh Report of the Joint
National Committee on Prevention, De-
tection, Evaluation, and Treatment of
High Blood Pressure (22) and KPNC
guidelines for diabetic patients of SBP
130 mmHg but is a conservative target
at which a diabetic patient most likely
needs therapy modiﬁcation. Good risk
factor control for patients with hyperlip-
idemia was deﬁned as an LDL cholesterol
value 100 mg/dl during the year (23).
Laboratory and blood pressure values for
2005 were obtained from automated
KPNC databases.
Treatment intensiﬁcation
A binary variable was created to indicate
whether pharmacy databases indicated
an intensiﬁcation of pharmacotherapy
within 6 months after an instance of
Table 1—Patient descriptive statistics
African
American Hispanic White
n 15,905 17,750 74,900
Age (years)
50 18 22 13
51–64 42 37 37
65–74 27 27 29
75 14 14 22
Sex
Male 45 50 53
Female 55 50 47
Language
English not primary language 1 22 2
Income
$30,000 15 10 6
$30,000–$49,999 40 32 29
$50,000–$64,999 21 26 25
$65,000–$84,999 18 24 25
$85,000 6 8 15
College degree
10% in census block 36 36 20
10–20% 33 35 34
20–30% 21 20 28
30% 10 8 18
Doctor choice
Assigned 17 23 22
Patient chose 32 32 32
Unknown 50 44 46
Physician specialty
Internal medicine 82 76 76
Family practice 11 16 17
Other specialty 7 8 7
Physician race/ethnicity
African American 10 3 3
Hispanic 4 11 4
White 40 36 47
Asian 44 46 42
Annual visits
To own primary care provider 2.4 2.4 2.4
To any primary care provider 3.6 3.5 3.4
To any primary care provider/registered nurse 4.6 4.3 4.3
Years with own primary care provider 6.3 5.6 6.0
Insulin at baseline 10 8 10
Smoker 16 11 13
No. of drug classes 8.3 7.4 8.2
Medicare 41 42 53
Medications at baseline
Diabetes medications
Sulfonylureas 39 43 38
Metformin 33 41 34
Insulin 12 11 12
Hyperlipidemia
Statins 54 56 62
Hypertension
ACE inhibitors 48 49 51
-Adrenergic blockers 32 28 36
Thiazides/related diuretics 36 24 27
Calcium channel blockers 30 16 18
Data are percent.
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6-month period (as used in previous
studies [4]) was chosen because the high
visitrateofdiabeticpatientswithinKPNC
and the use of primary care teams who
can reach out to initiate therapy modiﬁ-
cationonthephysician’sbehalfviaphone
or mail give sufﬁcient opportunity for
therapy modiﬁcation in this setting. In-
tensiﬁcation was deﬁned as an increase in
the number of drug classes, an increase in
dosageofatleastonedrugclass,oraswitch
to a different drug class within 6 months.
Daily doses were categorized as low (near
initial starting doses), medium (mainte-
nance range), or high (high end or above
maintenance range) based on package in-
sertrecommendationsandinspectionofac-
tualdosagedistributions.Patientswhowere
already using insulin were excluded from
the treatment intensiﬁcation for hypergly-
cemia analysis because treatment intensiﬁ-
cation for insulin cannot be measured in
automated pharmacy databases.
Main explanatory variables
Patient race/ethnicity. Patient race/
ethnicity was the main explanatory vari-
able for multivariable models that
assessed predictors of risk factor control
and treatment intensiﬁcation. In these
stratiﬁed (African American versus white
and Hispanic versus white) models, sep-
arate dummy variables were created for
African American and Hispanic race/
ethnicity, with white patients as the refer-
ence group. Similar dummy variables
were created for African American and
Hispanic physicians, with white physi-
cians as the reference group.
Patient-physician concordance. Pa-
tient-physician interaction terms were in-
cluded to assess the association of patient-
physician race/ethnicity concordance with
risk factor control and treatment intensiﬁ-




ginal effect of patient race/ethnicity and
patient-physician concordance on A1C,
LDL cholesterol, and SBP control and
intensiﬁcation. The resulting marginal
effects were converted into adjusted per-
centages of patients in good CVD risk fac-
tor control and patients at above-target
CVD risk factor levels who received treat-
ment intensiﬁcation. These models con-
trolled for patient age, sex, preferred
language, number of comorbidities, risk
factorvalues(fortreatmentintensiﬁcation
analysis),numberofprimarycarevisitsin
2005, Medicare status, number of medi-
cation classes taken for condition, overall
pill burden, geocoded education, and in-
come as ﬁxed effects. Physician age, sex,
race/ethnicity, language proﬁciency
(which is self-reported by physicians at
their onset of employment with the med-
ical group), panel size, and number of di-
abetic patients in panel were also
included as ﬁxed effects. To account for
patient clustering at the physician level,
allmodelsadjustedforphysicianasaran-
dom effect. Logistic regression models
were also run to conﬁrm the multivariate
ﬁndings.
This study was developed and ap-
proved by the Steering Committee of the
Translating Research in Action for Diabe-
tes (TRIAD) study and approved by the
KPNC Institutional Review Board. All
Table 2—Percentage of patients with good CVD risk factor control by race/ethnicity
African American patients Hispanic patients White patients
Unadjusted Adjusted OR (95% CI) Unadjusted Adjusted OR (95% CI) Unadjusted Adjusted
OR
(95% CI)
A1C 8% 65 64  0.6* 0.76 (0.71–0.81) 63 62 (0.7)* 0.69 (0.71–0.81) 74 69 Ref
LDL cholesterol
100 mg/dl 41 40  0.8* 0.71 (0.66–0.76) 47 49 (0.7)† 1.09 (1.02–1.16) 50 47 Ref





Table 3—Percentage of patients with good CVD risk factor control by race/ethnicity concordance
African American patients Hispanic patients
Unadjusted Adjusted OR (95% CI) Unadjusted Adjusted OR (95% CI)
A1C 8%
Concordant 66 65  1.7 1.07 (0.89–1.28) 62 63  1.5 0.94 (0.81–1.10)
Discordant 65 64 Ref 63 62 Ref
LDL cholesterol 100 mg/dl
Concordant 38 40  2.1 0.96 (0.79–1.16) 49 48  1.7 0.93 (0.79–1.08)
Discordant 42 40 Ref 48 49 Ref
SBP 140 mmHg
Concordant 68 69  1.6 0.95 (0.78–1.16) 76 76  1.4 0.93 (0.78–1.12)
Discordant 70 70 Ref 77 77 Ref
Data are %, %  SEM, and ORs (95% CI). Probit random effect and logistic models examined minority patient-physician race/ethnicity interactions. Models were
adjusted for patient age, sex, preferred language, number of comorbidities, number of primary care visits in 2005, Medicare status, number of medication classes
taken for condition, pill burden, geocoded education and income, physician age, sex, race/ethnicity, language, panel size, and number of diabetic patients in panel.
Race/ethnicity discordant patients are the referent (Ref) group.
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RESULTS— Approximatelyhalfofthe
patients in the sample were male (52%)
and almost 97% reported speaking at
least some English. Almost half of the pa-
tients (46%) were white, 11% were His-
panic, and 10% were African American.
Spanish was the primary language of al-
most a quarter (22%) of the Hispanic pa-
tients.Only10%ofAfricanAmericanand
11% of Hispanic patients were in race/
ethnicity concordant relationships with
their providers. Physicians were dispro-
portionately white (47%) or Asian (40%);
8% of physicians were either African
American or Hispanic. Patients were with
their primary care physicians for an aver-
age of 5.6–6.3 years (Table 1).
After controlling for patient and phy-
sician characteristics, patient race/
ethnicity was a signiﬁcant predictor of
risk factor control for all three risk factors
(Table2).AfricanAmericanpatientswere
less likely than whites to have A1C 8%
(64 vs. 69%, P  0.001). African Ameri-
canpatientswerealsolesslikelytobeator
belowtargetLDLcholesterol(40vs.47%,
P  0.001) and SBP (70 vs. 78%, P 
0.001). Hispanic patients were less likely
than whites to have A1C 8% (62 vs.
69%, P  0.001). Risk factor control var-
ied little and nonsigniﬁcantly by patient-
provider race/ethnicity concordance
(Table 3).
Table 4 shows the proportion of pa-
tients at above-target risk factor levels
who received treatment intensiﬁcation
within 6 months, by race/ethnicity, after
adjustment for patient and physician
characteristics. Patient race/ethnicity was
a signiﬁcant predictor of treatment inten-
siﬁcation for all three risk factors. African
American patients were less likely than
whitepatientstohaveA1Cintensiﬁcation
(73vs.77%,P0.0001)andmorelikely
to receive treatment intensiﬁcation for
SBP above target (78 vs. 71%, P 
0.0001). No signiﬁcant differences in
A1CorSBPintensiﬁcationwerefoundfor
Hispanic patients compared with white
patients. However, Hispanic patients
were more likely than white patients to
have treatment intensiﬁcation for LDL
cholesterol(47vs.45%,P0.05).Treat-
ment intensiﬁcation was not signiﬁcantly
associated with patient-physician race/
ethnicity concordance (Table 5). Race/
ethnicity and race/ethnicity concordance
effects on risk factor control and treat-
ment intensiﬁcation were consistent re-
gardlessofwhetherthepatient’spreferred
language was included in the model,
when cut points of A1C 7% and SBP
130 mmHg were used, and when insu-
linusewasadjustedforinmodelsoftreat-
ment intensiﬁcation for hyperglycemia
(data not shown).
CONCLUSIONS — Our ﬁndings are
consistent with previous research show-
ing racial disparities in CVD risk factor
control (2). African American patients
had worse risk factor control for A1C,
LDL cholesterol, and SBP than white pa-
tients. Hispanic patients had worse con-
trol for A1C than white patients. Unlike
previous research, after controlling for
patientandphysiciancharacteristics,His-
panicpatientswerenomorelikelytohave
Table 4—Percentage of patients receiving treatment intensiﬁcation (among patients with elevated risk factor values) by patient race/ethnicity
African American patients Hispanic patients White patients
Unadjusted Adjusted OR (95% CI) Unadjusted Adjusted OR (95% CI) Unadjusted Adjusted
OR
(95% CI)
A1C 8% 76 73  1.2* 0.82 (0.71–0.94) 77 75  1.1 0.92 (0.80–1.05) 78 77 Ref
LDL cholesterol
100 mg/dl 44 44  1.0 0.96 (0.87–1.04) 47 47  1.1† 1.1 (1.0–1.2) 43 45 Ref
SBP 140 mmHg 70 78  1.3‡ 1.47 (1.28–1.68) 77 74  1.5 1.1 (0.98–1.33) 78 71 Ref
Data are %, %  SEM, and ORs (95% CI). Physician random effect probit and logistic regression models were adjusted for patient age, sex, preferred language,
number of comorbidities, number of primary care visits in 2005, Medicare status, number of medication classes taken for condition, laboratory values, pill burden,
geocoded education and income, physician age, sex, race/ethnicity, language, panel size, and number of diabetic patients in panel. White patients are the referent
(Ref) group.*P  0.01; †P  0.05; ‡P  0.001.
Table 5—Percentage of patients receiving treatment intensiﬁcation by patient-physician race/ethnicity concordance
African American patients Hispanic patients
Unadjusted Adjusted OR (95% CI) Unadjusted Adjusted OR (95% CI)
A1C 8%
Concordant 72 73  3.1 0.99 (0.69–1.43) 77 75  2.7 1.04 (0.76–1.43)
Discordant 77 74 Ref 77 75 Ref
LDL cholesterol 100 mg/dl
Concordant 44 46  2.6 1.08 (0.85–1.37) 48 46  2.4 0.95 (0.77–1.16)
Discordant 44 44 Ref 47 47 Ref
SBP 140 mmHg
Concordant 69 76  3.5 0.87 (0.62–1.23) 75 80  3.4 1.35 (0.95–1.90)
Discordant 75 78 Ref 73 74 Ref
Data are %, %  SEM, and ORs (95% CI). Probit random effects and logistic model examined minority patient-physician race/ethnicity interactions. The model was
adjusted for patient age, sex, preferred language, number of comorbidities, number of primary care visits in 2005, Medicare status, number of medication classes
taken for condition, pill burden, geocoded education and income, physician age, sex, race/ethnicity, language, panel size, and number of diabetic patients in panel.
Race/ethnicity discordant patients are the referent (Ref) group.
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terol and SBP than white patients (3).
Our ﬁndings also provide evidence
supporting the hypothesis that race/
ethnicity is modestly associated with
treatment intensiﬁcation. We found dis-
parities in A1C intensiﬁcation in compar-
isons of African American patients with
white patients. We also found that, in
some cases, minority patients were more
likely to receive treatment intensiﬁcation
than whites. One potential explanation
for the greater likelihood of treatment in-
tensiﬁcation for African American pa-
tients with elevated SBP and Hispanics
with elevated LDL cholesterol compared
with whites is what is known as the sta-
tistical discrimination hypothesis: in in-
stances of uncertainty, physicians may
rely on what they know about the preva-
lence and consequences of the disease for
the racial group to which a particular pa-
tient belongs (24). Aware of high rates of
hypertension in African American pa-
tients and high cholesterol in Hispanic
patients,physiciansmaybemorelikelyto
intensify treatment.
Patient preferences may also drive
differencesintreatmentintensiﬁcationby
race/ethnicity. Studies have shown differ-
ential trust in the medical system for mi-
nority patients. Minority patients are
more likely than whites to perceive they
wouldhavereceivedbettermedicalcareif
theybelongedtoadifferentracialandeth-
nic group and that medical staff judged
them unfairly or treated them with disre-
spect based on race/ethnicity (25). These
barriers to trust may affect patients’ atti-
tudes toward medicine and may contrib-
ute to differential reluctance to intensify
therapy. On the other hand, it is also pos-
sible that African American patients may
be more anxious about elevated SBP than
white patients are.
Our ﬁndings do not support the hy-
pothesis that patient-physician race/
ethnicity concordance would improve
control of intermediate diabetes out-
comes. Previous research has shown that
equal or better care for minority patients
does not necessarily close gaps in health
outcomes between minority and white
patients (13), so it is quite possible that
potential beneﬁts of concordance would
not translate into (immediate) intermedi-
ate outcome improvement.
Several limitations to this study
should be noted. Patients and physicians
werefromasinglelarge,integratedhealth
caredeliverysystem;itispossiblethatpa-
tients and physicians in this setting may
be different from patients and physicians
in other settings. However, the patient
and physician populations studied were
fairly diverse, and the delivery system
population is demographically similar to
theregionitserves(3).Omittedvariables,
such as patient family history of stroke,
evidence of end-organ damage, and pa-
tient and physician attitudes and beliefs
regarding medication, were not captured
in these analyses and may inﬂuence dif-
ferential intensiﬁcation rates. Our vari-
ables were also limited by the fact that we
only had access to socioeconomic status
indicators from geocoding; individual-
level data on education and income were
not available in this study. Another limi-
tation is that we were unable to assess
treatment intensiﬁcation for A1C control
in patients who were already taking insu-
lin at the start of the study; it is possible
that this causes underestimation of the
level of intensiﬁcation in this population
and potentially biases differences in in-
tensiﬁcation rates for hyperglycemia by
race/ethnicity. We were also unable to
measure nonmedication treatment deci-
sions physicians make; in response to
poor control, physicians may provide
diet, exercise, and other lifestyle recom-
mendations that we are unable to include
in our analysis.
Another limitation of the study was
our inability to assess the impact of race/
ethnicity and race/ethnicity concordance
onriskfactorcontrolandtreatmentinten-
siﬁcationforAsiansandpatientsandphy-
sicians of other races/ethnicities. Future
research exploring ethnic and language
concordance in these populations is
indicated.
Finally, another potential reason we
did not detect signiﬁcant race/ethnicity
interaction effects is that many diabetic
patients also receive care from nutrition-
ists, health educators, and pharmacists
andpotentiallyfromotherphysiciansand
nurses. For example, patients may also
haveaccesstodiabetescareclassesprovided
by health educators. We were unable to as-
sess patient race/ethnicity concordance
with these and other medical care staff, and
these relationships may have played a role
in predicting risk factor control and
intensiﬁcation.
In summary, in this study, minority
race/ethnicity was a signiﬁcant predictor
of worse patient risk factor control and
better treatment intensiﬁcation. How-
ever, patient-physician race/ethnicity
concordance was not associated with ei-
ther control or treatment intensiﬁcation
for any risk factor. Future researchers
should try to illuminate the speciﬁc bar-
riers to intensiﬁcation, including possible
patient or physician cultural factors that
would inform targeted interventions to
improve both risk factor control and
treatment intensiﬁcation.
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